Summary Revance has soared 50% to all-time highs based on preliminary data from a Phase 2 study, which appeared to indicate that its RT002 was superior to Allergan’s Botox. Revance has deliberately shown misleading data and withheld the real information, which would actually be required for FDA approval. The CMO quit one day after the…

Read More